Novogen soars as subsidiary hits the fast track
Friday, 05 November, 2004
Investors added more than AUD$1 -- or 20 per cent -- to Novogen's (ASX:NRT) share price today on the news that the company's subsidiary Marshall Edwards (Nasdaq: MSHL/LSE AIM:MSH) had been granted fast-track status for the use of phenoxodiol in recurrent ovarian cancer.
The US Food and Drug Administration grants fast track review status to drugs that could treat an unmet medical need, making them eligible for accelerated marketing approval.
"We are developing phenoxodiol for the treatment of a wide range of cancers, but for the purpose of this fast track program, we are focusing on its use as a chemo-sensitising agent in recurrent, late-stage ovarian cance," said Marshall Edwards executive chairman Dr Graham Kelly in a statement.
Marshall Edwards is currently putting phenoxodiol through Phase II clinical trials as a stand-alone therapy and in combination with other drugs for the treatment of a range of cancers.
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
